Evidence map›Paper›PMID 11408205›Full record

ArticleAntimicrobial agents and chemotherapy2001

Search for new drugs for treatment of tuberculosis.

I Orme, Tuberculosis Drug Screening Program

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Article
  2. Ag(I) complexes with natural products and triphenylphosphine: activity against tumor cell lines and mycobacterium tuberculosis.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. ACS omega · 2025
    Article
  8. Article
  9. Review
  10. A newFuture microbiology · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

I OrmeDepartment of Microbiology, Colorado State University, Fort Collins, CO 80523, USA. iorme@lamar.colostate.edu
Tuberculosis Drug Screening Program

Funding

TB DRUG SCREENING:TB ANTIMICROBIAL ACQ &COORD. FACILITYN01AI095364 · NIAID · SOUTHERN RESEARCH INSTITUTE · PI SECRIST, JOHN A · 1999 to 2000
$778k
TUBERCULOSIS TECHNOLOGY TRANSFER SUPPORTN01AI095384 · NIAID · RESEARCH TRIANGLE INSTITUTE · PI ROUSE, DORIS · 1999 to 2000
$778k
ANIMAL MODEL TESTING OF TB DRUGSN01AI095385 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI ORME, IAN M · 1999 to 2000
$446k
Intramural NIH HHS Z01 AI005106NIAID NIH HHS AI-5106-04NIAID NIH HHS N01 AI095364NIAID NIH HHS N01 AI095384NIAID NIH HHS N01 AI095385
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntitubercular AgentsDisease Models, AnimalDrug Evaluation, PreclinicalHumansMiceMicrobial Sensitivity TestsMycobacterium tuberculosisNational Institutes of Health (U.S.)TuberculosisUnited StatesAntitubercular Agents

Identifiers

PMID11408205
PMCPMC90582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.